Skip to content

The mechanism of Shenlingbaizhu Powder for peptic ulcer treatment Efficacy and safety evaluation – retrospective cohort studies

The mechanism of Shenlingbaizhu Powder for peptic ulcer treatment Efficacy and safety evaluation – retrospective cohort studies

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070322
Enrollment
Unknown
Registered
2023-04-10
Start date
2023-04-10
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peptic ulcer

Interventions

Exposure group (Shenlingbaizhu Powder
Non-exposure group( other therapies):None

Sponsors

Nanchang Hongdu Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 18= age < 60 years old, male or female; Those who meet the clinical diagnostic criteria for spleen deficiency peptic ulcer;

Exclusion criteria

Exclusion criteria: 1. Diagnosed with gastric cancer; 2. Those with a history of gastrointestinal surgery; 3. Gastrointestinal hemorrhage, pyloric obstruction, perforation and other complications or severe heart, liver and kidney dysfunction; 4. Those suffering from hepatitis, cholecystitis, gallstones, pancreatic lesions; 5. Patients who have not taken the drug in accordance with the will, and there are patients who cannot evaluate the efficacy and data loss and other conditions that affect the efficacy or safety

Design outcomes

Primary

MeasureTime frame
Gastroscopic ulcers;

Secondary

MeasureTime frame
Helicobacter pylori (HP);

Countries

China

Contacts

Public ContactWan Qing; Xiaofan Chen

Jiangxi University of Traditional Chinese Medicine

xiaofanci122306@163.com+86 18507915566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026